AMDL Says Jade Pharmaceutical Sales Network Now Covers All of China
August 07 2007 - 6:00AM
PR Newswire (US)
TUSTIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin, China, through its wholly owned
subsidiary Jade Pharmaceutical Inc., said today that Jade has
completed development of a national sales network encompassing the
entire nation of China. Jade has expanded to include 75 full-time
sales representatives in its in-house sales force, explains Frank
Zheng, Managing Director. The balance of the nation is covered by
distribution partners. "The current focus is on 36 key Chinese
markets, in central, southeastern, eastern, northeastern and
southwest China," said Mr. Zheng. "Over the next 12 months, Jade
plans on expanding its sales network by 100 - 150 new sales
professionals who will be selling an expanded line of products.
Within the next four years, Jade will have a significant presence
in all 168 cities in China that have a population of more than one
million people." "This continued expansion of the sales force in a
focused, logical way will allow Jade to take full advantage of a
Chinese pharmaceutical market that is growing explosively," said
Gary Dreher, AMDL CEO. About Jade: Jade has access to the fastest
growing pharmaceutical and consumer market in the world: China.
AMDL, through its subsidiaries, Jade currently manufactures large
volume injection fluids, tablets and other related products,
holding licenses for 133 products. It also manufactures 107
generic, over the counter and supplemental pharmaceutical products
under certified Chinese Good Manufacturing Practice (CGMP)
standards. About AMDL: More information about AMDL and its products
can be obtained at http://www.amdl.com/. Forward-Looking
Statements: This news release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements are subject to certain risks and
uncertainties, and actual circumstances, events or results may
differ materially from those projected in such forward-looking
statements. The Company cautions readers not to place undue
reliance on any forward-looking statements. The Company does not
undertake, and specifically disclaims any obligation, to update or
revise such statements to reflect new circumstances or
unanticipated events as they occur. Contact: AMDL, Inc. Mr. Paul
Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice
Mail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul
Knopick, AMDL Investor Relations, Direct Line, +1-949-707-5365, or
Voice Mail, +1-714-505-4460 Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024